FLNAHIGH SIGNALFINANCIAL10-K

FLNA underwent a dramatic financial transformation with revenue surging 2000% while losses tripled and the balance sheet deteriorated significantly.

The massive revenue increase suggests either a major business pivot, acquisition, or operational scaling, but the tripling of losses indicates severe profitability challenges or one-time charges. The 49% decline in stockholders' equity combined with a 271% increase in liabilities signals potential financial distress or major restructuring that requires immediate investor attention.

Comparing 2026-03-12 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

FLNA experienced explosive revenue growth from $2M to $41.1M, but this came at a severe cost with net losses expanding from -$24.3M to -$91.0M despite R&D expenses declining 62%. The balance sheet shows concerning deterioration with stockholders' equity falling nearly 50% to $74.4M while liabilities quadrupled to $44M, though operating cash flow improved significantly from -$116.9M to -$32.3M. This financial profile suggests a company in major transition with scaling challenges that are burning through capital despite improved operational cash generation.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+2000.1%
$2.0M$41.1M

Strong top-line growth of 2000.1% — accelerating demand or successful expansion into new markets.

Capital Expenditure
Cash Flow
+464.1%
$103K$581K

Capital expenditure jumped 464.1% — major investment cycle underway; assess returns on deployment.

Net Income
P&L
-273.7%
-$24.3M-$91.0M

Net income declined 273.7% — review whether driven by operations, interest costs, or non-recurring items.

Current Liabilities
Balance Sheet
+273.1%
$11.8M$43.8M

Current liabilities surged 273.1% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+271.6%
$11.8M$44.0M

Liabilities grew 271.6% — significant increase in debt or obligations, assess impact on financial flexibility.

Operating Cash Flow
Cash Flow
+72.4%
-$116.9M-$32.3M

Operating cash flow surged 72.4% — exceptional cash generation, highest quality earnings signal.

R&D Expense
P&L
-61.8%
$69.6M$26.6M

R&D spending cut 61.8% — could signal cost discipline or concerning reduction in innovation investment.

Stockholders Equity
Balance Sheet
-48.9%
$145.7M$74.4M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Income
P&L
+32.6%
-$141.4M-$95.4M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Current Assets
Balance Sheet
-28.4%
$136.5M$97.7M

Current assets declined 28.4% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-03
ADDED
false --12-31 FY 2025 true true true false Our Director of Information Technology has responsibilities which include preventing and monitoring cybersecurity threats and utilizes the assistance of external vendors in this effort.
Our Director of Information Technology regularly reports to senior management regarding the status of our cybersecurity program, emerging cybersecurity threats, long-term cybersecurity investments and strategies, and oversight of our cybersecurity profile.
Our Director of Information Technology has responsibilities which include preventing and monitoring cybersecurity threats and utilizes the assistance of external vendors in this effort.
Our Director of Information Technology regularly reports to senior management regarding the status of our cybersecurity program, emerging cybersecurity threats, long-term cybersecurity investments and strategies, and oversight of our cybersecurity profile.
true Our full Board of Directors oversees the risk management process for the Company, which includes identifying, assessing and managing enterprise-level risks.
+7 more — sign up free →
REMOVED
sava20241231c_10k.htm 0001069530 CASSAVA SCIENCES INC false --12-31 FY 2024 true true false true Our full Board of Directors oversees the risk management process for the Company, which includes identifying, assessing and managing enterprise-level risks.
0.001 0.001 10,000,000 10,000,000 0 0 0 0 0.001 0.001 120,000,000 120,000,000 48,203,179 48,203,179 42,236,919 42,236,919 0 http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense 0 1 4 2 0 10 0 0 0 4.3 0 0 0 0 21 0 2020 2021 2022 2023 2024 4 4 1 4 2 1 1 3 2 2 4 16.9 1.5 0.1 0 0 0 0 0 0 false false false false Other segment items include interest income, other income, net and gain from change in fair value of warrant liabilities.
All statements other than statements of present or historical facts contained in this Annual Report, including statements anticipating or otherwise relating to our future results of operations and financial position, future results of clinical trials, business strategy, plans and objectives for future operations, and anticipated events or trends, are forward-looking statements.
In some cases, forward-looking statements are identified by terms such as aim, anticipate, believe, could, drive, estimate, expect, forecast, future, goal, intend, may, objective, plan, potential, project, seek, should, strategy, will and would or the negatives of these terms or other comparable terminology.
government inquiries; and litigation, claims or other uncertainties that may arise from allegations made against us or our former employees or collaborators.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →